A multi-center, real-world exploratory cohort study to evaluate cough frequency, severity, and impact on quality of life in patients with non-idiopathic pulmonary fibrosis interstitial lung disease

Completed

• Conditions: interstitial Lung disease; Pulmonary fibrosis; 10038716

• Registration Number: NL-OMON51461
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 2024-01-18
• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

- Provision of signed informed consent in writing prior to study data collection
- Subject aged 18 years or over
- Subject diagnosed with non-IPF fibrosing ILD

Exclusion Criteria

- Cough due to etiology other than ILD (e.g., allergic rhinitis,
Gastroesophageal Reflux Disease (GERD))
- Other respiratory disorders including, but not limited to, a current
diagnosis of any obstructive disease including chronic obstructive pulmonary
disease (COPD) and asthma, active tuberculosis, lung cancer in treatment or in
medical history, sleep apnea, known alpha-1 antitrypsin deficiency, cor
pulmonale, clinically significant pulmonary hypertension, clinically
significant bronchiectasis, or other active pulmonary diseases
- Respiratory infection or use of antibiotics for respiratory cause within 4
weeks prior to study entry
- Initiation or change in dose or type of anti-tussive medication,
angiotensin-converting enzyme (ACE) inhibitors, or corticosteroids in the 4
weeks prior to study entry
- Subject with airflow obstruction (forced expiratory volume in one second
(FEV1)/FVC<0.7) or known significant spirometry response to bronchodilator

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified